MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 180 Publications

19 Customer Reviews

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

  • Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

    IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.
Targets
Akt1 [1]
(Cell-free assay)		 Akt2 [1]
(Cell-free assay)		 Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 NVj2c5NZS3m2b4TvfIlkKEG|c3H5 NF;VT3Q{KM7:TR?= MkLFO|IhcA>? NWXvfGlOTE2VTx?= MWTJcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? MWKyNFU4OTB4OR?=
A431 Mnn4T4lv[XOnIFHzd4F6 MYC1JO69VQ>? NG\vVZA2KGh? MUfEUXNQ MlX5V5VxeHKnc4Pld{B1cGVic3nncoFtcW6pIH;mJGFsfCCjbnSgSZJs MUiyNFU4OTB4OR?=
HepG2 M3;DfWN6fG:2b4jpZ{BCe3OjeR?= M3S2fFExKM7:TR?= Mk\kNlQhcA>? MlnlSG1UVw>? MYrT[Y5{cXSrenXzJJJme2m|dHHueEBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDzc5Ji\mWwaXK= MYWyNVIxPTl{NR?=
Sk-Hep1 MkjQR5l1d3SxeHnjJGF{e2G7 MUmxNEDPxE1? NULRcXVQOjRiaB?= M1TvemROW09? MoPQV4Vve2m2aYrld{Bz\XOrc4ThcpQh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gd49z[W[nbnni NXvJUJpOOjF{MEW5NlU>
OCUT1 cells harbored PIK3CA (H1047R+/+) NWS3XYhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYKzJO69VQ>? NXW4[ZhFPSCm NFOzNm5FVVOR M3;5cGlEPTB;MD6xOEDPxE1? NYrCZpZTOjF{OEmyOlc>
K1 cells harbored PIK3CA (E542K+/+) MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe5THg{KM7:TR?= NYLXU4xUPSCm MlzwSG1UVw>? NUH3[3hrUUN3ME2wMlUzKM7:TR?= NFfCb3czOTJ6OUK2Oy=>
FTC133 cells harbored PTEN (allele deletion and R130+) MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID1Z2I{KM7:TR?= M{DWfVUh\A>? NHrUc41FVVOR MkDYTWM2OD1yLkG4JO69VQ>? MnuwNlEzQDl{Nke=
C643 cells harbored HRAS (G13R+/−) NYHXRmlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DmfVMh|ryP Mk\XOUBl MXHEUXNQ M2rReWlEPTB;MD6yO{DPxE1? NUTHV3c{OjF{OEmyOlc>
Hth7 cells harbored NRAS (Q61R+/−) MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXiW|k{KM7:TR?= NGjFSlA2KGR? MWnEUXNQ M4DPRWlEPTB;ND61JO69VQ>? NGqwe|MzOTJ6OUK2Oy=>
TPC1 cells harbored RET/PTC1 rearrangement MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuzJO69VQ>? MYK1JIQ> Moe1SG1UVw>? NHv0XI9KSzVyPUCuOVkh|ryP MmHONlEzQDl{Nke=
Hth74 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7EblROOyEQvF2= MYi1JIQ> MVnEUXNQ MlrwTWM2OD1{LkG5JO69VQ>? MYeyNVI5QTJ4Nx?=
KAT18 M2TmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnxd|NVOyEQvF2= MknkOUBl NYfKfJBXTE2VTx?= M{nHRmlEPTB;ND62NkDPxE1? MYeyNVI5QTJ4Nx?=
SW1736 NYjmcYFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[xNFAh|ryP M2DUWlUh\A>? M{DremROW09? Mnv6TWM2OD12Nz61OkDPxE1? Mly0NlEzQDl{Nke=
WRO MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:2dFExODBizszN NVza[IdXPSCm NVv6bFF1TE2VTx?= M4\2VWlEPTB-MUCwNEDPxE1? MY[yNVI5QTJ4Nx?=
TAD2 NGP3O2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\aN5cyODByIN88US=> MlqxOUBl MoC2SG1UVw>? NGfMfIhKSzVyPkGwNFAh|ryP NHvPVnYzOTJ6OUK2Oy=>
LN229 M3XzS2Fxd3C2b4Ppd{BCe3OjeR?= MlziNE42KM7:TR?= M3r0eVYxKGh? MoPNSG1UVw>? MlnxRZVodWWwdIOgZZBweHSxZ3XubYMh\W[oZXP0d{Bw\iCpZX\peIlvcWJ? MXGyNlA2PzlzNB?=
T98G M17h[2Fxd3C2b4Ppd{BCe3OjeR?= MoL0NE42KM7:TR?= NH\yU|A3OCCq NHf1Z2tFVVOR NF:zXVNCfWevZX70d{BieG:ydH;n[Y5q[yCnZn\lZ5R{KG:oIHfl[ol1cW6rYh?= NVHPb4xsOjJyNUe5NVQ>
HC11 NH22cXJHfW6ldHnvckBCe3OjeR?= MV2xNEDPxE1? MVyyOEBp NH3VZmRFVVOR NVPyVGJFUW6qaXLpeJMh|rJvY3Hz[YlvKGGwZDDBSHJRKHO7boTo[ZNqew>? M4DXSFIzPDJ4NkKx
MOLT-4 M{DKfWN6fG:2b4jpZ{BCe3OjeR?= M2rVO|ExKM7:TR?= MUC0PEBp NH7nRWxFVVOR Mn;6TWM2OD1zLkhihKnPxE1? MoXGNlI3OTR{NEO=
CEM-R NUHkT2JyS3m2b4TvfIlkKEG|c3H5 NGHiRncyOCEQvF2= NVfLbYRzPDhiaB?= NWjiWno4TE2VTx?= MYTJR|UxRTNwM,MAje69VQ>? M1vkZlIzPjF2MkSz
CEM-S MlrvR5l1d3SxeHnjJGF{e2G7 MlPNNVAh|ryP MoXrOFghcA>? NYi5[nFxTE2VTx?= NVfvepJSUUN3ME21MlHjiIoQvF2= NWqwNZJNOjJ4MUSyOFM>
MOLT-4 NEjneFdHfW6ldHnvckBCe3OjeR?= M2HHRVExKM7:TR?= Mme2NlQhcA>? NUTYb5M3TE2VTx?= NVfSU4JVSmyxY3vzJINmdGy|IHnuJJRp\SCJMD;HNUBxcGG|ZTDv[kB1cGViY3XscEBkgWOuZR?= NHX4[YUzOjZzNEK0Ny=>
MOLT-4 NFf0fXVHfW6ldHnvckBCe3OjeR?= M4LEdVTjiIoQvF2= NXLWcYx2PCCq NV3aTm9nTE2VTx?= MXzJcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFM1GvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI> NH:2cWEzOjZzNEK0Ny=>
CEM-R MoTKSpVv[3Srb36gRZN{[Xl? MnvPOQKBkc7:TR?= NHfEV4c1KGh? M37scWROW09? NV3wWZNLUW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|RCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{ NFfteJgzOjZzNEK0Ny=>
CEM-S MVTGeY5kfGmxbjDBd5NigQ>? MmXGOQKBkc7:TR?= NGHlW4U1KGh? MVnEUXNQ NULaeGc4UW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|VCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{ MUCyNlYyPDJ2Mx?=
HepG2 cell NIPpWm5McW6jc3WgRZN{[Xl? NWPFbZJyOjBizszN NImweVIzPCCq MVfEUXNQ M3PJO2Rwf26{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R? NFLPRXQzOzd7N{OxPS=>
HepG2 cell MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Gzb|MxKM7:TR?= MUGyOEBp M4TPRWROW09? NFm5XoFKdmirYnn0d{Bk\WyuIHfyc5d1cA>? Mn7PNlM4QTd|MUm=
HepG2 cell NUnaWm83SXCxcITvd4l{KEG|c3H5 MVGyNEDPxE1? NX7JNZFDOjRiaB?= NELy[nRFVVOR NG\Je2RKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NF;EZmozOzd7N{OxPS=>
GEO M{jXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX64cXpoPTByIH7N MVi3NkBp NYq3cVk3TE2VTx?= MnrYTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MoizNlQ2QDF{M{G=
CNE-1 NEfPSWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTON3lKOTBizszN MWe5OkBp NVPVcI9ITE2VTx?= MojzTWM2OD1{Lkm2JO69VQ>? Mo\3NlU{OzZ7MkW=
CNE-2 MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTyNVAh|ryP M2i5OFk3KGh? MXfEUXNQ M4rIfGlEPTB;ND61N{DPxE1? MkXGNlU{OzZ7MkW=
HONE-1 M3LmVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHOe3dlOTBizszN MnzKPVYhcA>? MVnEUXNQ M{H1cGlEPTB;Mz6zO{DPxE1? M2DzZVI2OzN4OUK1
SUNE-1 MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXSNVAh|ryP M3vjWVk3KGh? NIrod5hFVVOR NXXhNXNIUUN3ME2wMlUzKM7:TR?= MWqyOVM{Pjl{NR?=
CNE-2 MVTGeY5kfGmxbjDBd5NigQ>? MkLwNVAh|ryP NFq5SI01QCCq NWHP[YFzTE2VTx?= MnjUTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBIOQ>? NHfxXXIzPTN|NkmyOS=>
HONE-1 NV\LU5Y2TnWwY4Tpc44hSXO|YYm= NGnwemkyOCEQvF2= NGrBUYc1QCCq MnfkSG1UVw>? NYLEXGI1UW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCJMR?= M4HuNlI2OzN4OUK1
NEC8 M1PsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfyOGNKSzVyPUCuNFk3PTFizszN MUnTRW5ITVJ?
P12-ICHIKAWA MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu3dIpzUUN3ME2wMlEyPjJizszN NYHGUZc3W0GQR1XS
MDA-MB-175-VII MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrXOGtoUUN3ME2wMlE{PzN6IN88US=> M2rubHNCVkeHUh?=
AsPC-1 NGOwcmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TxTWlEPTB;MD6yNlEzOiEQvF2= NHf0WGJUSU6JRWK=
T47D MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HSTGlEPTB;MD6yPFI2KM7:TR?= Mkf6V2FPT0WU
HH MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvDSZM{UUN3ME2wMlMxOjh|IN88US=> MlfpV2FPT0WU
MOLT-16 NGnBe3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnv[YFKSzVyPUCuN|A{OiEQvF2= MV\TRW5ITVJ?
ES5 M1LEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DsW2lEPTB;MD6zOFQ2PSEQvF2= NF7tZ2VUSU6JRWK=
RS4-11 MoK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zyVmlEPTB;MD6zOFYyKM7:TR?= NUjsO4FpW0GQR1XS
KARPAS-45 MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXmTWM2OD1yLkO3N|IyKM7:TR?= NHTjVnFUSU6JRWK=
NCI-H720 M1zxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jzOmlEPTB;MD6zO|Y4QSEQvF2= NF7uRVJUSU6JRWK=
H9 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjnVGZEUUN3ME2wMlM5QDh|IN88US=> MUPTRW5ITVJ?
EFM-19 M2n4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHn3T3VKSzVyPUCuOFQxOSEQvF2= MWjTRW5ITVJ?
SBC-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jKV2lEPTB;MD60OFA{PSEQvF2= M3zLVXNCVkeHUh?=
A4-Fuk MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwNE[4Olgh|ryP M1S4cnNCVkeHUh?=
NCI-H1563 M2HMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzMXVRKSzVyPUCuOFgyQDlizszN MnLjV2FPT0WU
HCC1419 NWnrWZJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvRO4ZKSzVyPUCuOFg5QTJizszN NXHh[IJxW0GQR1XS
H-EMC-SS NYfLVnNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwNEm5N|kh|ryP NGPWfGdUSU6JRWK=
BHT-101 NH7FRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\G[WlEPTB;MD61Nlk3OSEQvF2= MkG5V2FPT0WU
IGROV-1 M4jheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwNUWyOFkh|ryP MWfTRW5ITVJ?
HGC-27 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlS1TWM2OD1yLkW2O|g{KM7:TR?= NVW1ZXFUW0GQR1XS
MDA-MB-361 M{jZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml34TWM2OD1yLkW3O|YyKM7:TR?= MkfEV2FPT0WU
KE-37 MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\p[2lEPTB;MD61PFI3KM7:TR?= MoTVV2FPT0WU
HCC70 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwNUm4Nlch|ryP NXy1Wm5jW0GQR1XS
LNCaP-Clone-FGC M{jiTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnZVXRvUUN3ME2wMlYyODR6IN88US=> NU\1WnVbW0GQR1XS
HAL-01 M{PNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M333NGlEPTB;MD62NlE{KM7:TR?= NXnXclFLW0GQR1XS
HT MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3DXlRIUUN3ME2wMlY{OjN7IN88US=> M3fWeXNCVkeHUh?=
MDA-MB-415 NHnIenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3faSmlEPTB;MD62N|YzPiEQvF2= NHH2WoZUSU6JRWK=
NOS-1 NGniNWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;qWIhjUUN3ME2wMlY{PzJ|IN88US=> NFvhWIVUSU6JRWK=
DU-145 MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTDTWM2OD1yLk[0O|Q2KM7:TR?= NH\lVWNUSU6JRWK=
OCUB-M NYG4UnFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr2[XVvUUN3ME2wMlcxQTZ4IN88US=> NYXo[JhOW0GQR1XS
VA-ES-BJ NYDkbVV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTZfYZzUUN3ME2wMlc{ODJ3IN88US=> NYC3WZpqW0GQR1XS
J-RT3-T3-5 NYDCO5BlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fJfmlEPTB;MD63OFQxOyEQvF2= M3y0b3NCVkeHUh?=
MOLT-4 NUWwNmVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XtcmlEPTB;MD64NFU5OiEQvF2= NGjLepZUSU6JRWK=
NB7 M{HMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj6XmxNUUN3ME2wMlgzPDFzIN88US=> Mon2V2FPT0WU
L-363 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17JcmlEPTB;MD64N|Q1OiEQvF2= MUfTRW5ITVJ?
NKM-1 NVPsUldCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXyTWM2OD1yLki2NlU{KM7:TR?= NWrtVJVnW0GQR1XS
HOP-92 M1L4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwOEeyNlMh|ryP NWrUdm9kW0GQR1XS
OAW-42 NVPWd4I6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnewTWM2OD1yLki4O|Ih|ryP NWq4[40{W0GQR1XS
HuO9 M3vhRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nv[WlEPTB;MD65Nlc2OSEQvF2= NWfHSYtSW0GQR1XS
MFE-280 NYqyN3pMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwOU[0OlUh|ryP MVfTRW5ITVJ?
EM-2 M{HlcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXaNHhOUUN3ME2wMlk4QTN7IN88US=> M3PmbnNCVkeHUh?=
NCI-H520 M3XFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwOUi1PVIh|ryP MlW1V2FPT0WU
LB2241-RCC MkTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvITlBKSzVyPUCuPVk4OzRizszN NHz0UYpUSU6JRWK=
SK-NEP-1 Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HnVWlEPTB;MT6xOFQ5PSEQvF2= NYO4N|BxW0GQR1XS
LXF-289 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFwMUexOVYh|ryP NELaS4ZUSU6JRWK=
EPLC-272H MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rmNGlEPTB;MT6xO|I2PiEQvF2= NFjlXIFUSU6JRWK=
COLO-684 MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;YNFZKSzVyPUGuNlM4OjVizszN NVPrUWhwW0GQR1XS
ES1 NFHi[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO4TWM2OD1zLkK0NFY2KM7:TR?= NXjJcGhZW0GQR1XS
DOHH-2 M1rhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\OTWM2OD1zLkK4NlA{KM7:TR?= MVHTRW5ITVJ?
CTB-1 MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm3TWM2OD1zLkK4PVkh|ryP NYnpbY9LW0GQR1XS
G-401 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXsUHFXUUN3ME2xMlI6Pzl3IN88US=> M{ThbHNCVkeHUh?=
LoVo NYf6TJNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfkT29PUUN3ME2xMlMzPTN2IN88US=> MWPTRW5ITVJ?
Ramos-2G6-4C10 NF;KXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTFwM{O3NFEh|ryP MlroV2FPT0WU
MFM-223 M2fQbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXEcIpVUUN3ME2xMlM1PDZzIN88US=> MWDTRW5ITVJ?
PA-1 M1W5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLQTWM2OD1zLkO1NlY2KM7:TR?= MVTTRW5ITVJ?
697 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXUTWM2OD1zLkO3OlE3KM7:TR?= M4L6WHNCVkeHUh?=
QIMR-WIL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwNEmxNVYh|ryP Mn3LV2FPT0WU
HOS MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL5PJhKSzVyPUGuOFk2PThizszN MmLPV2FPT0WU
DMS-273 NEXkXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LjSmlEPTB;MT61NVk2QSEQvF2= MnfKV2FPT0WU
ME-180 MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjaTWM2OD1zLkW2PFkyKM7:TR?= NXvmZYJ2W0GQR1XS
HCC2218 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjKTWM2OD1zLk[4NlI2KM7:TR?= NHTqdXJUSU6JRWK=
CAL-54 MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\ITWM2OD1zLkexNlQzKM7:TR?= MWXTRW5ITVJ?
OMC-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTqTWM2OD1zLke0Olc4KM7:TR?= Mmi3V2FPT0WU
COR-L105 NGDvVnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[yS4dSUUN3ME2xMlc6PzN5IN88US=> MmrKV2FPT0WU
BV-173 NV7kXGF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DNVGlEPTB;MT64NVA4PCEQvF2= MXTTRW5ITVJ?
RKO NXz4UVZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDSTWM2OD1zLki3NVAyKM7:TR?= MY\TRW5ITVJ?
SNU-387 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTje|RPUUN3ME2xMlg5PDB4IN88US=> NHjXVWdUSU6JRWK=
SW1088 NGfIb2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjGTYEzUUN3ME2xMlk1PjB4IN88US=> MkLHV2FPT0WU
Hs-578-T NIO1bZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTJwMUG0N|Mh|ryP NXjDR21uW0GQR1XS
OC-314 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrGW4pxUUN3ME2yMlE2ODh4IN88US=> M2r3VHNCVkeHUh?=
RMG-I NEfXZ3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrTOm1LUUN3ME2yMlE3Ozl6IN88US=> MofYV2FPT0WU
NCI-H1395 M1jHd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnziTWM2OD1{LkG4NFkyKM7:TR?= NWnz[Y1TW0GQR1XS
GAMG NUTreldHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHDTWM2OD1{LkKzPFQ2KM7:TR?= M1fKRXNCVkeHUh?=
LB1047-RCC MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHyyZo9KSzVyPUKuNlQ{OTdizszN MUDTRW5ITVJ?
MN-60 MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\YUmlEPTB;Mj6yPVkzOyEQvF2= M4O5SHNCVkeHUh?=
OAW-28 NVTlWFJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJwMkm5OVEh|ryP MkixV2FPT0WU
NCI-H2228 Ml;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\QOmlEPTB;Mj6zNVU2OiEQvF2= NGT6eIpUSU6JRWK=
ABC-1 NY\VRoZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXkeoZMUUN3ME2yMlM{OjV|IN88US=> MYDTRW5ITVJ?
LS-513 NF;5e4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvQTWM2OD1{LkOzOFg1KM7:TR?= NGTtWYpUSU6JRWK=
KS-1 NFfJUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlK1TWM2OD1{LkO4NVkyKM7:TR?= MnTmV2FPT0WU
NB69 NGTXNHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrGZVdKSzVyPUKuN|g6QDNizszN NI\iZYlUSU6JRWK=
VM-CUB-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3PTWM2OD1{LkO5NFg{KM7:TR?= NFOxc2NUSU6JRWK=
D-423MG Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;zTWM2OD1{LkSxNFQ1KM7:TR?= NGHQblRUSU6JRWK=
EW-18 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjs[VJ5UUN3ME2yMlQyQTN7IN88US=> NIfpNnNUSU6JRWK=
YH-13 MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;I[5lKSzVyPUKuOFYyPTNizszN MUHTRW5ITVJ?
T-24 NX;NPYRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfB[lNKSzVyPUKuOFc5QDFizszN NWH3eno5W0GQR1XS
ES8 NEPUcVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e2emlEPTB;Mj60PVI5PyEQvF2= MULTRW5ITVJ?
ES3 NHLjbXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknNTWM2OD1{LkS5O|U6KM7:TR?= MYfTRW5ITVJ?
RXF393 M3jpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJwNkC0PFch|ryP M4fzPXNCVkeHUh?=
RPMI-8226 NGjzfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPZTWM2OD1{Lk[yPVU{KM7:TR?= M4fQS3NCVkeHUh?=
AGS NHPE[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\wPJEyUUN3ME2yMlczOTN5IN88US=> M2Hib3NCVkeHUh?=
HCC1395 MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X3fGlEPTB;Mj63OVE5PyEQvF2= M{fsU3NCVkeHUh?=
MV-4-11 NXSyV5JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJwN{WyOlYh|ryP M4jJUHNCVkeHUh?=
A204 M4PhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mli2TWM2OD1{LkizPFczKM7:TR?= MYXTRW5ITVJ?
MCF7 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTWRXJKSzVyPUKuPFYyOTdizszN MVHTRW5ITVJ?
SNU-423 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3W1UGlEPTB;Mj64PVI1OiEQvF2= MonhV2FPT0WU
NCI-H1048 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvaTWM2OD1{Lkm2PFY2KM7:TR?= MUDTRW5ITVJ?
GR-ST MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[wNXRxUUN3ME2zMlA1PjFzIN88US=> MV\TRW5ITVJ?
EoL-1- MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S0RmlEPTB;Mz6wO|A2QCEQvF2= M1XvUnNCVkeHUh?=
HuH-7 MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnqTWM2OD1|LkC5OFY1KM7:TR?= NI[xUG1USU6JRWK=
OS-RC-2 NILiTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTNwMUGxPUDPxE1? MlrKV2FPT0WU
EW-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTNwMUm1Nlkh|ryP MVLTRW5ITVJ?
NCI-H747 NWjRXG1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvsTWM2OD1|LkKwOlk1KM7:TR?= MnzsV2FPT0WU
EW-16 M4[1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ryV2lEPTB;Mz6yNVg4QSEQvF2= M2HYcXNCVkeHUh?=
DOK MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTNwMkK4OVkh|ryP M3;uSHNCVkeHUh?=
HCC2157 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnIZ4pKSzVyPUOuN|gyPzlizszN NEDydnhUSU6JRWK=
OVCAR-3 Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPZTWM2OD1|LkSwO|g3KM7:TR?= M3;tSHNCVkeHUh?=
NCI-H1623 NGfLe5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTNwNEGyNlQh|ryP NU\oSVBwW0GQR1XS
H4 NF;pS|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEC5RlJKSzVyPUOuOFU3OjZizszN NGLrbVlUSU6JRWK=
SW1710 NH;SflRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DISGlEPTB;Mz60OlY4QCEQvF2= MlizV2FPT0WU
RT-112 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LvOWlEPTB;Mz61NlM5QCEQvF2= MkPJV2FPT0WU
DMS-114 NIDzTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;MXYl6UUN3ME2zMlYzOjd6IN88US=> NEHBUJZUSU6JRWK=
AN3-CA MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jadmlEPTB;Mz62NlQ2PiEQvF2= NVfafnJFW0GQR1XS
KNS-62 NYTLemRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPpUmFKSzVyPUOuOlM{OzhizszN MU\TRW5ITVJ?
SJRH30 NXPIN4prT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFn0cmdKSzVyPUOuOlkyOjJizszN MlHuV2FPT0WU
G-402 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7aZlkyUUN3ME2zMlcxPzFzIN88US=> MlXEV2FPT0WU
MHH-PREB-1 NIfLSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXSU5ZKSzVyPUOuO|IxOzhizszN M3v5O3NCVkeHUh?=
P30-OHK MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLBTWM2OD1|LkiwPVc3KM7:TR?= M1\2O3NCVkeHUh?=
RVH-421 NF3KdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3DV3FTUUN3ME2zMlgyPzh6IN88US=> NUizNZpyW0GQR1XS
LU-134-A MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTNwOEi0Nlgh|ryP M3jsdXNCVkeHUh?=
ECC10 NFTCTVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\vV2lEPTB;Mz65N|YzOiEQvF2= NI\ldZNUSU6JRWK=
TGW MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXTW3RKSzVyPUSuNFI{ODVizszN MkL5V2FPT0WU
MLMA MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUO5S5k6UUN3ME20MlAzQTZ4IN88US=> MX3TRW5ITVJ?
SCC-25 M3\2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LUSGlEPTB;ND6wOlU3PiEQvF2= NXfMVZpmW0GQR1XS
TYK-nu NHT6bY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7t[oxKSzVyPUSuNFk2OzRizszN NVm3eGxxW0GQR1XS
LAMA-84 MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTRwMUSxPVEh|ryP NIq3e4JUSU6JRWK=
Calu-3 M4LqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL6TWM2OD12LkK0OFE3KM7:TR?= M1noWHNCVkeHUh?=
NCI-H460 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHvTWM2OD12LkK2OFQ{KM7:TR?= Ml35V2FPT0WU
EGI-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTRwM{e3O|gh|ryP Mm[3V2FPT0WU
NCI-H292 Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DUWWlEPTB;ND6zPFE1PiEQvF2= M2i3PXNCVkeHUh?=
HCE-T NWX6dY5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;OSGFVUUN3ME20MlQyPTd7IN88US=> M1\BXXNCVkeHUh?=
EW-11 M{DG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH2wV25KSzVyPUSuOFE5OzhizszN MkH3V2FPT0WU
ATN-1 MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;KcZVtUUN3ME20MlQ1OzB2IN88US=> NHfNc4NUSU6JRWK=
NB5 M4LlW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Gxd2lEPTB;ND61N|Y6PyEQvF2= M4nrXnNCVkeHUh?=
KLE M37CfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH5ToRKSzVyPUSuO|AyQThizszN NU\oSFdQW0GQR1XS
CAL-39 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTRwN{KxOFYh|ryP NEi0[opUSU6JRWK=
TI-73 NXHT[4JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPDfnl4UUN3ME20MlgxPjB7IN88US=> NWrJOXpkW0GQR1XS
HO-1-N-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHX5TIVKSzVyPUSuPVQzKM7:TR?= M2jJN3NCVkeHUh?=
786-0 MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnuwTWM2OD12Lkm0Olc{KM7:TR?= MYHTRW5ITVJ?
SK-N-DZ MlnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3xTWM2OD12Lkm2NVQzKM7:TR?= M4n4eXNCVkeHUh?=
NCI-H446 MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTCTWM2OD13LkKwNFA6KM7:TR?= Mk\uV2FPT0WU
ETK-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTVwMkGxOlUh|ryP NYPGeVBoW0GQR1XS
BT-20 M4H5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M361NGlEPTB;NT6yNVM2OyEQvF2= MYnTRW5ITVJ?
MEL-HO NGfGVlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PJWmlEPTB;NT6zO|M{PiEQvF2= NF[1ZnpUSU6JRWK=
CAL-27 NGDmfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH4fW9KSzVyPUWuOFY{OzlizszN M1jFNHNCVkeHUh?=
SW872 M1vTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\oTWM2OD13LkW5OFI5KM7:TR?= NHXpeY9USU6JRWK=
RPMI-2650 NHXtfFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTVwNk[xPVkh|ryP MonwV2FPT0WU
PFSK-1 MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTKTWM2OD13LkeyO|MzKM7:TR?= Mn7iV2FPT0WU
SF295 M3PNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzmb5drUUN3ME21MlgxPjN|IN88US=> M1\HSXNCVkeHUh?=
Becker MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTVwOE[0O|Ih|ryP M{TjbXNCVkeHUh?=
Saos-2 NGe1dYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTVwOE[1N{DPxE1? MWTTRW5ITVJ?
SK-OV-3 NGPRUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTVwOUm4NVYh|ryP NGTxUFlUSU6JRWK=
VMRC-RCZ M3LHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ezTWlEPTB;Nj6wPFc4OyEQvF2= NIq5RWFUSU6JRWK=
EW-22 MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljzTWM2OD14LkG5OlQ6KM7:TR?= MnLTV2FPT0WU
BT-474 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XlbmlEPTB;Nj6yN|Mh|ryP MWnTRW5ITVJ?
BFTC-909 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1KzNGlEPTB;Nj6zNFM1PSEQvF2= MXfTRW5ITVJ?
NB12 NEXteXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17hbmlEPTB;Nj6zPVA4OSEQvF2= MXnTRW5ITVJ?
D-263MG NHj3[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHBZWdKSzVyPU[uOFUyPjlizszN NV3yOnd7W0GQR1XS
SNB75 Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\1emlEPTB;Nj62NFE1OyEQvF2= NYjRWXNKW0GQR1XS
A704 MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTZwNkOwOkDPxE1? M2n2eHNCVkeHUh?=
NCI-H1693 NFj0OGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvkXGVWUUN3ME22MlY{PjB2IN88US=> MoDaV2FPT0WU
LN-405 NH7NTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXSVHRmUUN3ME22Mlc6Pjd{IN88US=> NX3seIFTW0GQR1XS
CHL-1 NED5So5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTZwOECwO|kh|ryP MXzTRW5ITVJ?
A498 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTZwOEG5OlEh|ryP MXTTRW5ITVJ?
TE-12 NGfyc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLITWM2OD14LkizPFE4KM7:TR?= NXX5PWR2W0GQR1XS
TE-6 MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTZwOUOwN|gh|ryP M{fGbnNCVkeHUh?=
AU565 M3fSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTZwOU[5OVch|ryP M3zob3NCVkeHUh?=
RD M1X5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD1TWM2OD14Lkm4Nlg1KM7:TR?= NHT0NnBUSU6JRWK=
SW1463 NXfVWok{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHnTWM2OD15LkGxNVY5KM7:TR?= NHXNWIdUSU6JRWK=
LU-99A MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LnRmlEPTB;Nz6xOFMzOiEQvF2= NXrLfGluW0GQR1XS
NCI-H28 MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3ET2NMUUN3ME23MlI6OjRizszN M1WyWHNCVkeHUh?=
MC-IXC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHqTWM2OD15LkS4OVc3KM7:TR?= MkHUV2FPT0WU
GP5d MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHaSphKSzVyPUeuOFg4PjRizszN MYfTRW5ITVJ?
GB-1 NXXuOXB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDJRYk6UUN3ME23MlU1QDB2IN88US=> MmXzV2FPT0WU
CAL-33 NFm1doNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTdwNk[yN|Mh|ryP MoPPV2FPT0WU
MSTO-211H MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7STWM2OD15Lk[3N|M3KM7:TR?= MULTRW5ITVJ?
TE-5 M4r5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHnTWM2OD15Lke5N|M1KM7:TR?= Mnm0V2FPT0WU
D-566MG Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRThwMES0Nlkh|ryP NFH3W4xUSU6JRWK=
JVM-3 NUfQfJpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\Pd5pKSzVyPUiuNVUzPjhizszN MkX5V2FPT0WU
T98G M4i2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3NTWM2OD16LkG4NFY4KM7:TR?= NELkTYtUSU6JRWK=
HCC1954 Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVS3U3lzUUN3ME24MlQ2OTB2IN88US=> M{\IfXNCVkeHUh?=
SF126 NU\GfFNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XjPWlEPTB;OD60OVk{PiEQvF2= MUjTRW5ITVJ?
LB996-RCC MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRThwNUOyOVch|ryP NXvVdpdVW0GQR1XS
SKG-IIIa Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LyNGlEPTB;OD62N|A3QSEQvF2= NX7DRWI5W0GQR1XS
NCI-SNU-1 NFjyTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf6RpZyUUN3ME24MlY1PjR|IN88US=> NUe3[JI4W0GQR1XS
LB771-HNC M4fM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRThwNkS2PVYh|ryP NGXVO4xUSU6JRWK=
SCC-4 NWHBSJQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnBXplKSzVyPUiuOlgzOTlizszN MVfTRW5ITVJ?
CAMA-1 NIDFOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\tRWlEPTB;OD63O|E1PiEQvF2= NX;lbo56W0GQR1XS
D-502MG NF22NIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrye2ZKSzVyPUiuO|g3OjlizszN Ml25V2FPT0WU
ESS-1 NYjGdWc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPGTWM2OD16Lki4O|A1KM7:TR?= NHq3PJlUSU6JRWK=
HEC-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\IPXZKSzVyPUiuPFk5PjZizszN MYjTRW5ITVJ?
NB10 NIHoUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvpTWM2OD17LkCyNlI1KM7:TR?= M2jwSXNCVkeHUh?=
8505C MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTlwMESyN|Ih|ryP MlzQV2FPT0WU
EFO-27 NVfvU2o2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTiTWM2OD17LkG2OFEzKM7:TR?= M2nPZ3NCVkeHUh?=
HN NHfIRY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDkTWM2OD17LkG2OlI5KM7:TR?= MYLTRW5ITVJ?
DSH1 M3OxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnFTWM2OD17LkKwPFch|ryP MVrTRW5ITVJ?
NBsusSR NEj5O4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fMPWlEPTB;OT6yO|QxOiEQvF2= MXrTRW5ITVJ?
LS-123 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\Hd2VKSzVyPUmuN|E4PjFizszN MXjTRW5ITVJ?
SHP-77 NXjPdFlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjYZoRKSzVyPUmuN|k6OzVizszN NX3ZfIJoW0GQR1XS
ACN MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTHeXRnUUN3ME25MlU{Ojd5IN88US=> MXzTRW5ITVJ?
U251 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVqxVWVEUUN3ME25MlY2PTR2IN88US=> NFqyNm1USU6JRWK=
A431 NFj4OYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml31TWM2OD17LkiwNlM5KM7:TR?= M2jlR3NCVkeHUh?=
5637 MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\aTWM2OD17Lki0PVg1KM7:TR?= MojTV2FPT0WU
MDA-MB-157 NXy1[IJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PkRWlEPTB;OT65Nlg4QCEQvF2= MYfTRW5ITVJ?
A101D MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTlwOUm5O|Qh|ryP MUjTRW5ITVJ?
YKG-1 NUPjR2hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrpTZZwUUN3ME2xNE4zODB4IN88US=> NWXH[Xp{W0GQR1XS
LAN-6 M{\h[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PvUmlEPTB;MUCuNlE3PCEQvF2= MoDWV2FPT0WU
OVCAR-5 NITNT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v2b2lEPTB;MUCuNlQ{OyEQvF2= NGPyZ41USU6JRWK=
A549 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTFyLkO5O|Mh|ryP NEm4TGNUSU6JRWK=
no-11 Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnFNZFQUUN3ME2xNE41OzV|IN88US=> M1;ifnNCVkeHUh?=
SF539 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjFcnlRUUN3ME2xNE46ODRzIN88US=> NI\GUJdUSU6JRWK=
A388 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;3[mhKSzVyPUGxMlM5QTdizszN NIDXXpVUSU6JRWK=
DEL MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDYTWM2OD1zMT60NlQh|ryP Mmi3V2FPT0WU
SW954 NEi3cppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFzLkS2Olgh|ryP NXHPfVNYW0GQR1XS
TK10 MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFzLkWyO|Eh|ryP NVvYelBWW0GQR1XS
SW756 NHjvUIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFzLkWyPVQh|ryP MYTTRW5ITVJ?
PC-3 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTiT4xKSzVyPUGxMlU4PjRizszN M1XDUnNCVkeHUh?=
ONS-76 NEPHdotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;KT2lEPTB;MUGuOlM3KM7:TR?= NWq0SZlIW0GQR1XS
A427 NV7Sb3ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X3[2lEPTB;MUGuO|A6OyEQvF2= MoryV2FPT0WU
MEG-01 M4r2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFzLke1NFkh|ryP NX\sToVmW0GQR1XS
BB30-HNC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H1fGlEPTB;MUGuO|k5OiEQvF2= MlnEV2FPT0WU
NCI-H1299 Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{O2SGlEPTB;MUGuPFA6OyEQvF2= M13PTXNCVkeHUh?=
GCT MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF2wPHFKSzVyPUGxMlgzOjhizszN NE\5NGtUSU6JRWK=
D-247MG MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe3cGRqUUN3ME2xNU46PjZ|IN88US=> NW\BdZN5W0GQR1XS
CFPAC-1 M1GzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnSZ5BLUUN3ME2xNU46Pzh{IN88US=> Ml3wV2FPT0WU
EKVX NXTFUYZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PrcGlEPTB;MUKuNFMyOyEQvF2= MWLTRW5ITVJ?
CAL-51 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPJfHk3UUN3ME2xNk4xPzF4IN88US=> MVnTRW5ITVJ?
BB49-HNC M17pSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDK[Ip3UUN3ME2xNk4yOTd5IN88US=> NYLXRllpW0GQR1XS
RPMI-7951 NG\lWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHB[lFqUUN3ME2xNk4yQDV2IN88US=> NWi3coZ{W0GQR1XS
RH-1 NYXsbXl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f2d2lEPTB;MUKuNlE5PCEQvF2= NVXNbVZrW0GQR1XS
BCPAP MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnUTWM2OD1zMj60O|Q6KM7:TR?= MVvTRW5ITVJ?
GCIY NXrrVZFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojGTWM2OD1zMj61NlA6KM7:TR?= Mon0V2FPT0WU
KNS-81-FD MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTF{LkW4Olkh|ryP NHTQUoxUSU6JRWK=
KYSE-140 NXXKSlh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PjeWlEPTB;MUKuPFU6PSEQvF2= MVPTRW5ITVJ?
Ca-Ski NFzFVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4naN2lEPTB;MUKuPVA1OSEQvF2= NFr0bW1USU6JRWK=
TGBC1TKB M1HwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\BZmlEPTB;MUKuPVEyPSEQvF2= NIPrZppUSU6JRWK=
HCC1187 MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\zTWM2OD1zMz6xPVEzKM7:TR?= MonWV2FPT0WU
SJSA-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\4ZWlEPTB;MUOuNlMzPyEQvF2= NGP4NmpUSU6JRWK=
CTV-1 MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;mZ3NNUUN3ME2xN{4{PDVizszN NEPaenpUSU6JRWK=
WM-115 NEniRpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP4XmM3UUN3ME2xN{43PDh|IN88US=> NHOz[|lUSU6JRWK=
CHP-212 MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D6N2lEPTB;MUOuPVc{QSEQvF2= MWXTRW5ITVJ?
SCC-15 NIDRO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPBfm5KSzVyPUGzMlk4PzVizszN M2HZeHNCVkeHUh?=
BPH-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF2LkG2OlQh|ryP NFm4SoJUSU6JRWK=
SW780 NEm2VI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF2LkWwNlUh|ryP NF;5dndUSU6JRWK=
NCI-H2291 M1vTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rrXGlEPTB;MUSuOVg4QCEQvF2= MlK3V2FPT0WU
JEG-3 NWrhcWZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\uOWw2UUN3ME2xOE43OzJ4IN88US=> NYSxXJJIW0GQR1XS
CAL-120 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmGxTWM2OD1zND63NFI4KM7:TR?= NYXlO3dVW0GQR1XS
NCI-H23 MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXqS3ltUUN3ME2xOE44QTl5IN88US=> NH7rR4lUSU6JRWK=
MS-1 M1yzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLX[21mUUN3ME2xOE46PjFzIN88US=> Ml2zV2FPT0WU
PC-14 Mo\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL4eHJkUUN3ME2xOE46PjV2IN88US=> M4XmUXNCVkeHUh?=
D-283MED MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;BfZNKSzVyPUG1MlAyOTFizszN M1vVUnNCVkeHUh?=
OE19 MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTF3LkG1OFEh|ryP NWD1eYVYW0GQR1XS
CAS-1 MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDjfZQ6UUN3ME2xOU41OTh2IN88US=> M1XIeHNCVkeHUh?=
NCI-H727 MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn0TWM2OD1zNT60NlIyKM7:TR?= M2X1[HNCVkeHUh?=
SiHa MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHW[pJKSzVyPUG1Mlc2QTRizszN MVrTRW5ITVJ?
BFTC-905 MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M16ySWlEPTB;MUWuO|Y6PCEQvF2= M1XIenNCVkeHUh?=
MDA-MB-453 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPnV2k6UUN3ME2xOk4yPjR{IN88US=> MnfhV2FPT0WU
HuP-T3 NYThVFExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fpXWlEPTB;MU[uOlM4OyEQvF2= NFrselZUSU6JRWK=
SK-LU-1 MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjYUJlpUUN3ME2xOk43QTV4IN88US=> M37zbnNCVkeHUh?=
Detroit562 MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGOxUVRKSzVyPUG2Mlc{OThizszN NIi4UmZUSU6JRWK=
HCC1569 NYqyWmxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF4LkizN|ch|ryP NVz6ZmZIW0GQR1XS
SK-MES-1 NFTEbY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHG5[GNKSzVyPUG2Mlg1OTlizszN NYXpXXM2W0GQR1XS
BB65-RCC MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTF5LkC0O|kh|ryP MnXBV2FPT0WU
LOXIMVI Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPLTWM2OD1zNz6wO|A4KM7:TR?= MV;TRW5ITVJ?
SW1783 NX3vbYE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjuR|JKSzVyPUG3MlEzQCEQvF2= NHHPVWRUSU6JRWK=
NH-12 NIDIbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rnUWlEPTB;MUeuN|MxOyEQvF2= MnXtV2FPT0WU
UACC-257 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHvWoZKSzVyPUG3MlU2OTJizszN MUnTRW5ITVJ?
KOSC-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXDTI0{UUN3ME2xO{43PzV5IN88US=> MorMV2FPT0WU
KG-1 NEnJUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml2xTWM2OD1zNz62PVM4KM7:TR?= MnmwV2FPT0WU
M059J M1z4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfMZlJKSzVyPUG3MlcxOyEQvF2= NWPqZZFlW0GQR1XS
MHH-NB-11 NUW4RZk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF5Lkm2O|Mh|ryP NWrIfo5vW0GQR1XS
EW-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3oTWM2OD1zOD6xN|gzKM7:TR?= NHrISopUSU6JRWK=
CAL-85-1 M3LOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF6LkKzOVch|ryP MVrTRW5ITVJ?
639-V MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnwbmZ[UUN3ME2xPE4{OzV2IN88US=> MYDTRW5ITVJ?
C32 NFnsbVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfZTWM2OD1zOD60O|I4KM7:TR?= MUDTRW5ITVJ?
KM-H2 MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF6LkWyN|Ih|ryP M3L4THNCVkeHUh?=
A253 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjrO45KSzVyPUG4MlczQDZizszN M3jXeXNCVkeHUh?=
NCI-N87 NV;kTmZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS2TWM2OD1zOD65NFA5KM7:TR?= MVzTRW5ITVJ?
8-MG-BA M324cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7OcG9KSzVyPUG5MlA3PDZizszN NYHJSFVSW0GQR1XS
GI-ME-N NIjt[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlf6TWM2OD1zOT6xOVQ3KM7:TR?= NUDxOGxEW0GQR1XS
8305C NEDONYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O3XmlEPTB;MUmuNlI5PiEQvF2= MUTTRW5ITVJ?
TE-8 MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETFUotKSzVyPUG5MlMxOjRizszN M3HscXNCVkeHUh?=
KYSE-270 NH\SfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnGe2tKSzVyPUKwMlAzOTdizszN M{TjbHNCVkeHUh?=
HL-60 M{i4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHKUoZQUUN3ME2yNE4xQTRzIN88US=> NXz3OFBJW0GQR1XS
Mo-T NUPZbFV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f5N2lEPTB;MkCuNVY3PSEQvF2= NEPDU5lUSU6JRWK=
NCI-H1355 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3NOWh5UUN3ME2yNE4{Ozd2IN88US=> Ml3sV2FPT0WU
HT-1080 NULwS2xCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrIOpBTUUN3ME2yNE42PDl5IN88US=> MoGxV2FPT0WU
MIA-PaCa-2 NHW4b4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjSc29KSzVyPUKwMlY5QDNizszN M{nLT3NCVkeHUh?=
NCI-H441 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJyLkezO|kh|ryP Mm\jV2FPT0WU
LCLC-97TM1 MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzxTWM2OD1{MD64NVM1KM7:TR?= NX31cJRbW0GQR1XS
HT-3 NUnDU4M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHSTWM2OD1{MT61OlMyKM7:TR?= NWfle2RGW0GQR1XS
22RV1 M17pfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TkWWlEPTB;MkGuOVY5PSEQvF2= MoHtV2FPT0WU
LK-2 NHuzWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLsTWM2OD1{MT61PVU{KM7:TR?= M{n2XnNCVkeHUh?=
CW-2 NH3TXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7RTWM2OD1{MT62NFY6KM7:TR?= MmjLV2FPT0WU
KYSE-510 M3S1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIq1Rm5KSzVyPUKxMlYxQTVizszN MW\TRW5ITVJ?
CGTH-W-1 MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHXPWRKSzVyPUKxMlcyPjZizszN M3izVHNCVkeHUh?=
NCI-H661 MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfWSWJWUUN3ME2yNk4xOzRizszN NWT5XWpDW0GQR1XS
KU-19-19 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\qdGlEPTB;MkKuNVY6PyEQvF2= NGPzZWdUSU6JRWK=
NCI-H2122 M{PpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnZTW1KSzVyPUKyMlI1OzJizszN MYXTRW5ITVJ?
NCI-H526 M1\q[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jre2lEPTB;MkKuN|g6PSEQvF2= MVvTRW5ITVJ?
NCI-H1650 MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDjWXJKSzVyPUKyMlc3PCEQvF2= M3TRTXNCVkeHUh?=
AM-38 MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PLcmlEPTB;MkKuPFY5QSEQvF2= M4PlR3NCVkeHUh?=
NCI-H2405 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\xXmVKSzVyPUKzMlI2OzNizszN MYTTRW5ITVJ?
M14 MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fWNGlEPTB;MkOuOFA5QCEQvF2= MXPTRW5ITVJ?
ES4 NFLlV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHLO3dZUUN3ME2yN{41OjN{IN88US=> M4PFZnNCVkeHUh?=
DJM-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2exOGlEPTB;MkOuOVI{PCEQvF2= NVq2RoF{W0GQR1XS
S-117 MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS1bIwzUUN3ME2yN{44PjVzIN88US=> M{\PNHNCVkeHUh?=
MZ2-MEL NWLUTWZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X0R2lEPTB;MkOuO|c2QSEQvF2= MWfTRW5ITVJ?
SK-MEL-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljvTWM2OD1{Mz64NVM{KM7:TR?= NFLme5NUSU6JRWK=
HCC1806 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHWTWM2OD1{Mz64O|A6KM7:TR?= M4jhOXNCVkeHUh?=
NMC-G1 MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\uXIh[UUN3ME2yOE4zOjJ4IN88US=> MnPSV2FPT0WU
DK-MG NUPuToR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzGU2dKSzVyPUK0MlI6PCEQvF2= M2TlNnNCVkeHUh?=
SK-N-FI NYf4XnJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLhZ4hTUUN3ME2yOE4{OzB{IN88US=> MWTTRW5ITVJ?
KINGS-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33MSmlEPTB;MkSuOFg4PCEQvF2= NVHPUIpCW0GQR1XS
HCC2998 M1\pOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny0TWM2OD1{ND60PFg2KM7:TR?= NWiyO4d7W0GQR1XS
ALL-PO MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LISGlEPTB;MkSuOlE6KM7:TR?= M{D5XHNCVkeHUh?=
MPP-89 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\UTWM2OD1{NT6wOFU5KM7:TR?= NGTmVWRUSU6JRWK=
NCI-H2342 NHHlNIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJ3LkG5OVMh|ryP MnvpV2FPT0WU
TE-1 NH3zPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTJ3LkO1OlMh|ryP MlO0V2FPT0WU
RH-18 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJ3LkW5NVgh|ryP MnfaV2FPT0WU
HT-1376 M1zqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDqTWM2OD1{NT62OFY2KM7:TR?= M3vxOHNCVkeHUh?=
U-2-OS NH;Pbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37qSGlEPTB;MkWuOlg5QCEQvF2= MWTTRW5ITVJ?
BT-549 M2PhUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJ3LkmwNVEh|ryP MWDTRW5ITVJ?
NCI-H1755 M4LZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDRTWM2OD1{NT65PVQ2KM7:TR?= NEfWeItUSU6JRWK=
EW-13 M1H3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfwTpVKSzVyPUK2MlAzPzRizszN M{LsW3NCVkeHUh?=
NB13 M{fmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1y3WWlEPTB;Mk[uNFk1QSEQvF2= Ml;VV2FPT0WU
NUGC-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJ4LkKxNFMh|ryP NFSzNWZUSU6JRWK=
GMS-10 NVu5dI9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\qTWM2OD1{Nj6yN|U{KM7:TR?= NFWxfolUSU6JRWK=
CHP-134 Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jZRWlEPTB;Mk[uN|g3PyEQvF2= NUDlPGN4W0GQR1XS
SW962 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXqRYNwUUN3ME2yOk42ODJzIN88US=> NFPaUnFUSU6JRWK=
SNU-449 NUTTVXNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vGbGlEPTB;MkeuNFgxOyEQvF2= Mn[wV2FPT0WU
HuP-T4 NH3JcXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPXOoQ3UUN3ME2yO{4xQDd7IN88US=> MVHTRW5ITVJ?
SW948 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLhc2lKSzVyPUK3MlE{PDRizszN NF:4b3dUSU6JRWK=
NCI-H226 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Xob2lEPTB;MkeuOFU4QCEQvF2= NXvJe3NVW0GQR1XS
SK-PN-DW MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnGeWNuUUN3ME2yO{43ODF{IN88US=> M{jobnNCVkeHUh?=
GI-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJ5LkeyNUDPxE1? NWjKOmxHW0GQR1XS
CAL-12T MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfsZYlrUUN3ME2yPE4yOTF{IN88US=> NYrx[VdVW0GQR1XS
YAPC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7nTWM2OD1{OD6yOVY1KM7:TR?= MlraV2FPT0WU
SNU-C2B MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rSdGlEPTB;MkiuNlk3PCEQvF2= NHX0XppUSU6JRWK=
RCC10RGB MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJ6LkW0NVch|ryP MoDjV2FPT0WU
ES7 NELzemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPXbGlKSzVyPUK5MlE1PjVizszN NFT2WZRUSU6JRWK=
PANC-03-27 M1fGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTJ7LkS0OEDPxE1? MU\TRW5ITVJ?
ES6 M1HafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXyycIk1UUN3ME2yPU45OTV5IN88US=> MmXtV2FPT0WU
HT-1197 M3TZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\VUY9DUUN3ME2zNE4xPTl6IN88US=> NVHVVolXW0GQR1XS
ZR-75-30 NUHnToxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzPe3kzUUN3ME2zNE4zOzh|IN88US=> MUXTRW5ITVJ?
DB Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P2OmlEPTB;M{CuOFk1OiEQvF2= NHLxbWNUSU6JRWK=
OCI-AML2 MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PCUmlEPTB;M{GuNFY6KM7:TR?= Mnq0V2FPT0WU
NCI-H2170 MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{X2dWlEPTB;M{GuPFUyPiEQvF2= MlrqV2FPT0WU
IST-MES1 NF7UOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W1OGlEPTB;M{KuNlg6PyEQvF2= M4PmNnNCVkeHUh?=
769-P NX;yWZBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Dvc2lEPTB;M{KuN|Y1OSEQvF2= MV;TRW5ITVJ?
COR-L23 NYThWXdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrTe3VTUUN3ME2zNk46ODd|IN88US=> NHPmNI1USU6JRWK=
SW626 Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTPZYxSUUN3ME2zN{4yPzd4IN88US=> MX7TRW5ITVJ?
LU-139 MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTN|Lk[2NFUh|ryP MU\TRW5ITVJ?
HT-144 NE\HdWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\nU|ltUUN3ME2zN{45PjNizszN MU\TRW5ITVJ?
CaR-1 NFvSN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP4fVhKSzVyPUOzMlk5OjJizszN NF\t[mRUSU6JRWK=
OE33 NH\1UYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIi1fWhKSzVyPUO0MlI5PTVizszN NHS4Tm1USU6JRWK=
COLO-800 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTRTWM2OD1|ND6zOlQ4KM7:TR?= NFvLPVFUSU6JRWK=
NB14 MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnTOFNKSzVyPUO0MlQ3QDRizszN MlW2V2FPT0WU
KURAMOCHI MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\iNnFKSzVyPUO2MlEyQThizszN NF;sSXdUSU6JRWK=
SW48 NYmwVJNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy2PGNTUUN3ME2zOk4zPDd2IN88US=> M1nUbXNCVkeHUh?=
Daoy M2[zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLjTWM2OD1|Nj62OVM5KM7:TR?= NF3YSG9USU6JRWK=
TGBC24TKB Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzr[XdKSzVyPUO2MlY4KM7:TR?= NX\ufpNpW0GQR1XS
DU-4475 MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LadWlEPTB;M{[uPVA{OyEQvF2= MUXTRW5ITVJ?
SW1417 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTPcXIyUUN3ME2zPE4xPTV{IN88US=> NEH3TIRUSU6JRWK=
EFO-21 Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvhZ|dKSzVyPUO4Mlk{PDlizszN M2nYWHNCVkeHUh?=
MG-63 NGLpfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFW5OHNKSzVyPUO5MlM1OjRizszN NXzuRnlxW0GQR1XS
LC-2-ad M{nufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nneGlEPTB;M{muOVUyOiEQvF2= NUnOeopUW0GQR1XS
NOMO-1 M4P6W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjMO5dmUUN3ME2zPU45Ojd2IN88US=> NGHQSnpUSU6JRWK=
COLO-741 NHP0PYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jIZ2lEPTB;NECuNVMxPCEQvF2= Ml63V2FPT0WU
BxPC-3 M37FN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTRyLkW2PFYh|ryP M4SzOXNCVkeHUh?=
HSC-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTRyLkmxNVMh|ryP NGXXTIpUSU6JRWK=
UMC-11 Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\3UItpUUN3ME20NU4zPjNizszN NW[0fGVoW0GQR1XS
HCC1937 MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzETWM2OD12Mj63PFQ{KM7:TR?= NFv2bFdUSU6JRWK=
Calu-6 MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS5VGNKSzVyPUSzMlI{QDJizszN NEXGWndUSU6JRWK=
NCI-H1573 MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzXNIFKSzVyPUSzMlM1PzdizszN M3TldXNCVkeHUh?=
SK-N-AS NVHV[lZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHezV2hKSzVyPUSzMlYxOTlizszN M1TYcnNCVkeHUh?=
PSN1 MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvwNoVKSzVyPUS1MlI2PDhizszN Mn3QV2FPT0WU
TE-11 MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TTPWlEPTB;NEWuOFg1OiEQvF2= MX3TRW5ITVJ?
NCI-H1155 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDnfY5KSzVyPUS1Mlg6PjdizszN NVHRSZZJW0GQR1XS
KM12 M{\ufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrxTWM2OD12NT65NFc3KM7:TR?= NYnleFdoW0GQR1XS
RO82-W-1 NYjTUW1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\EWlNPUUN3ME20Ok46QDJ{IN88US=> NHvs[WJUSU6JRWK=
SW1573 NVvrPWw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7tNFA5UUN3ME20O{4{PzN4IN88US=> M4PjZ3NCVkeHUh?=
CAKI-1 NHiyO|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTR6LkK4OFUh|ryP M4L2PHNCVkeHUh?=
U-118-MG MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n1TWlEPTB;NEiuN|cxOiEQvF2= NXHwSIs3W0GQR1XS
KYSE-520 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q4bmlEPTB;NEiuOFAyPiEQvF2= NVPIS4NCW0GQR1XS
HT55 NHHn[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;0TWM2OD12OT6xOFc1KM7:TR?= M4G1PXNCVkeHUh?=
ChaGo-K-1 MmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTR7LkS3PVMh|ryP MXrTRW5ITVJ?
IA-LM MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTV2Lk[zNlIh|ryP NXLXR4JsW0GQR1XS
UACC-62 M{KwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTqdmNZUUN3ME21OU4yODR4IN88US=> NHzI[mlUSU6JRWK=
MKN7 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXETWM2OD13Nj6wNlg2KM7:TR?= MorTV2FPT0WU
HPAF-II MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTETWM2OD13Nj60NFc{KM7:TR?= M1e0SXNCVkeHUh?=
NTERA-S-cl-D1 NVrLV2ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTV5Lke3PEDPxE1? M2Tx[3NCVkeHUh?=
FTC-133 NETU[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TpO2lEPTB;NUiuNFk3QSEQvF2= M16zc3NCVkeHUh?=
MHH-ES-1 MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF72eIdKSzVyPUW4MlQ5OTRizszN M3rDVnNCVkeHUh?=
JVM-2 NWfrWWlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHO1RVFKSzVyPUW4Mlk2ODZizszN MXrTRW5ITVJ?
TCCSUP NFXXOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37VUWlEPTB;NUmuOVI4QSEQvF2= MoLYV2FPT0WU
COLO-824 M1P1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm1RZl{UUN3ME22NE4xPzF7IN88US=> MV;TRW5ITVJ?
647-V MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTZyLkGzOFch|ryP MlLLV2FPT0WU
HD-MY-Z NXfqO4Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTZyLkWyPVQh|ryP MVXTRW5ITVJ?
LS-411N MoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jC[WlEPTB;NkGuN|kxOyEQvF2= MYPTRW5ITVJ?
NCI-H596 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzOeHJKSzVyPU[yMlc1QTZizszN MYHTRW5ITVJ?
C-33-A NVL0dphMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLkTWM2OD14ND6wPVU4KM7:TR?= MYjTRW5ITVJ?
BHY MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\idIM2UUN3ME22OE4yOjR3IN88US=> NH;i[25USU6JRWK=
KGN Ml3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPSTWM2OD14ND61OVE1KM7:TR?= M2nGXXNCVkeHUh?=
NCI-H1092 NWTJTY5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTZ3LkCwPVUh|ryP M3fvcHNCVkeHUh?=
MZ1-PC NYPNfoJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLiTWM2OD14NT61OlQ6KM7:TR?= MkfBV2FPT0WU
LB831-BLC MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T6O2lEPTB;NkWuPFQ5OSEQvF2= MYjTRW5ITVJ?
SW620 NG\TeYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTZ4LkKwN|kh|ryP NETMUG9USU6JRWK=
HuO-3N1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfhW5BKSzVyPU[4MlMzOzhizszN MVzTRW5ITVJ?
SK-HEP-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTZ7Lkm0PFYh|ryP Mn7NV2FPT0WU
LCLC-103H MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknOTWM2OD15MD62O|A2KM7:TR?= MWLTRW5ITVJ?
KYSE-70 NUPGOFVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXwTVFKSzVyPUewMlc5OzVizszN M2Dl[nNCVkeHUh?=
Mewo MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nsZWlEPTB;N{GuOVA2KM7:TR?= NE\CWFBUSU6JRWK=
COLO-668 NH\PO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTdzLki0OVEh|ryP NXrUXpBQW0GQR1XS
NCI-H522 M322bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHkWWZKSzVyPUeyMlM1OTNizszN NYH2fHdFW0GQR1XS
NCI-H1437 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHESGlZUUN3ME23OE41ODR6IN88US=> MYfTRW5ITVJ?
U-266 NHjCbmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfSOVdKSzVyPUe1MlQ2OTZizszN MWHTRW5ITVJ?
MC116 NGTTOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7n[m9KSzVyPUe1MlU4ODhizszN M{\HfXNCVkeHUh?=
PANC-10-05 NHnSbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HWTmlEPTB;N{euOFI1OyEQvF2= NGi2b4NUSU6JRWK=
KYSE-180 NETK[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTCUXVzUUN3ME23O{42PDV2IN88US=> MnvQV2FPT0WU
JAR NFr3V3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPSTWM2OD15OT6wOVQ3KM7:TR?= M{LaVXNCVkeHUh?=
CAL-62 M2jyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLWe2hIUUN3ME24NE4xQTVizszN NWnub2lkW0GQR1XS
A3-KAW NYH0S2Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TmbWlEPTB;OECuNlE2PCEQvF2= NH23OINUSU6JRWK=
PANC-08-13 MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRThzLkG3Olgh|ryP NV7Tb5BuW0GQR1XS
HSC-3 M3njZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTh|LkOwO|Eh|ryP M1v0OXNCVkeHUh?=
HTC-C3 NIrsdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nKT2lEPTB;OEOuOFcxOiEQvF2= MV\TRW5ITVJ?
KY821 M2TpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTJTWM2OD16ND6wPFkzKM7:TR?= MlfhV2FPT0WU
DoTc2-4510 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Hr[WlEPTB;OESuNlE5PSEQvF2= M4e4W3NCVkeHUh?=
NCI-H1581 M{nVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrDXVVKSzVyPUi1MlQ3PDFizszN MYLTRW5ITVJ?
KARPAS-299 M2HoeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPqTWM2OD16Nj6xPVc4KM7:TR?= NVXrXIJTW0GQR1XS
IST-MEL1 Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3zUINuUUN3ME24Ok45QDd{IN88US=> NGDqZmhUSU6JRWK=
KP-N-YS M1O0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfxfnhKSzVyPUi5MlkxOjhizszN M33sSXNCVkeHUh?=
KYSE-410 MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTlzLkSwOFIh|ryP Mn7kV2FPT0WU
TE-10 MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjNSZFKSzVyPUmxMlU3OTFizszN NWnLPHVEW0GQR1XS
SK-MEL-1 MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYH1ZYN{UUN3ME25Nk46OTB4IN88US=> M4XudnNCVkeHUh?=
COLO-792 NVLxNXJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\3TWM2OD17NT6yOVY1KM7:TR?= NHzS[XFUSU6JRWK=
SCH NHTpVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LWeWlEPTB;OU[uN|g4PyEQvF2= MlK4V2FPT0WU
NCI-H1792 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXhRXJKSzVyPUm2Mlg6QTJizszN NXfETJcxW0GQR1XS
NCI-H2029 Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HafmlEPTB;OU[uPVU3PiEQvF2= MXjTRW5ITVJ?
SW684 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHqeXZKSzVyPUm4MlY3PTRizszN M2HCc3NCVkeHUh?=
NCI-H209 NXj0Nm5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nOVWlEPTB;MUCwMlEzOSEQvF2= M4LIbXNCVkeHUh?=
HLE M3X6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnPbW5zUUN3ME2xNFUvOjh{IN88US=> M{XlWnNCVkeHUh?=
GOTO MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEmwTJpKSzVyPUGwO{44PzdizszN M2fDTnNCVkeHUh?=
NCI-H1793 M1v1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXyWYhVUUN3ME2xNFkvOjhizszN M3LU[nNCVkeHUh?=
D-392MG M1;qeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17IbWlEPTB;MUG3MlM6QCEQvF2= NV62XZpGW0GQR1XS
SW1990 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkT6TWM2OD1zMkCuPVUyKM7:TR?= NGD0NXlUSU6JRWK=
ML-2 M3ntRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXLSYVKSzVyPUGyNU43PzZizszN NGHmSFhUSU6JRWK=
NCI-H2452 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXyXFJ4UUN3ME2xNlIvOjFizszN NEHBUWhUSU6JRWK=
SK-MEL-30 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rkZWlEPTB;MUKzMlI1PCEQvF2= M1W5enNCVkeHUh?=
SN12C MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDBWWxvUUN3ME2xNlQvOTd4IN88US=> NILMXG9USU6JRWK=
NCI-H1770 NEe1V4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H5[GlEPTB;MUK1MlUyPCEQvF2= MoKyV2FPT0WU
SF268 M3\sO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXOc|JKSzVyPUGyOk4yPThizszN NXLIVIJwW0GQR1XS
BALL-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHTOVdKSzVyPUGyOk4zOyEQvF2= M{X0cnNCVkeHUh?=
COLO-679 NIrHeo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHyxU5FKSzVyPUGyOk44PTNizszN M1vLOHNCVkeHUh?=
A2780 NG\X[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFGxdWFKSzVyPUGyPE46QDhizszN NX\BUpJ6W0GQR1XS
NCI-H1651 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTXeINSUUN3ME2xN|EvOjR|IN88US=> Ml3wV2FPT0WU
NCI-H2087 NGTCXWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTF|MT60PFMh|ryP M33uc3NCVkeHUh?=
U-87-MG MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvxTWM2OD1zM{OuOlA1KM7:TR?= NYT5NWRiW0GQR1XS
LB2518-MEL MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHLV3NjUUN3ME2xN|UvQTl|IN88US=> MV7TRW5ITVJ?
HCT-116 M3[1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LVemlEPTB;MUO3MlIyPyEQvF2= NXrRNphzW0GQR1XS
Ca9-22 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF|OT64N|Mh|ryP Ml3GV2FPT0WU
COR-L88 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Xub2lEPTB;MUSyMlE1KM7:TR?= NIf2ZYVUSU6JRWK=
CP50-MEL-B MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvDWndKSzVyPUG0OE42ODFizszN NXTKOGZOW0GQR1XS
OVCAR-8 NIT1b49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDOR|huUUN3ME2xOFUvPjN4IN88US=> MnXxV2FPT0WU
SK-MEL-3 MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\FV3lbUUN3ME2xOFcvQDd6IN88US=> NHnRNpVUSU6JRWK=
GT3TKB NHjnfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnezTWM2OD1zNEmuPVI5KM7:TR?= NFPQOVNUSU6JRWK=
KYSE-450 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPYTWM2OD1zNUGuOVM6KM7:TR?= MWjTRW5ITVJ?
CAPAN-1 NWrTZlE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHzOJM1UUN3ME2xOVMvODZ2IN88US=> MnnQV2FPT0WU
BEN NYS3N3NqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;zeGlEPTB;MUWzMlkzQCEQvF2= M3n1S3NCVkeHUh?=
NCI-H1304 M2CxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3yxd2lEPTB;MUW0MlY6PCEQvF2= NF7o[ZNUSU6JRWK=
KU812 MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTqbG9xUUN3ME2xOVgvPjd2IN88US=> MoizV2FPT0WU
Capan-2 NImzUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTF4MD61OVMh|ryP MlPTV2FPT0WU
A673 NI\D[GFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX4bZJOUUN3ME2xOlEvPzB3IN88US=> NFfBXphUSU6JRWK=
SAS MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzvbJFKSzVyPUG2Nk43PzhizszN M3ewRnNCVkeHUh?=
NY MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXy0Oo1xUUN3ME2xOlUvOzF2IN88US=> MXjTRW5ITVJ?
HCE-4 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG0ZWRuUUN3ME2xOlYvQDR3IN88US=> MUXTRW5ITVJ?
MDA-MB-231 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTF5Nz61NFMh|ryP M1fn[nNCVkeHUh?=
no-10 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF5OD6xN|Qh|ryP MVfTRW5ITVJ?
MZ7-mel NX7z[nNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrmTWM2OD1zN{iuOFY4KM7:TR?= MYfTRW5ITVJ?
NCI-H82 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTF6MD6xOlUh|ryP NYj5XGVxW0GQR1XS
CAL-72 M3zLW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF6NT6wOVQh|ryP MWfTRW5ITVJ?
NCI-SNU-5 NWHrUXlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHTTWM2OD1zOE[uPFQh|ryP NEXaRXFUSU6JRWK=
OVCAR-4 M1ThNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjWOoVKSzVyPUG4PE4{OzNizszN NGHSco5USU6JRWK=
SCC-9 MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHUdIlKSzVyPUG5NUDPxE1? NX22cmZUW0GQR1XS
KYSE-150 NYnVemtoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nHN2lEPTB;MUmxMlg5QCEQvF2= NFrmOohUSU6JRWK=
HT-29 M{WxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TCdWlEPTB;MkCxMlIyOiEQvF2= NHLxVoVUSU6JRWK=
COLO-678 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LPT2lEPTB;MkCxMlQ2KM7:TR?= NInjPZZUSU6JRWK=
NCI-H650 NXK3PWJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJyMj6xNFMh|ryP M{iyb3NCVkeHUh?=
HuCCT1 NGT3OnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvGTWM2OD1{MESuNlA5KM7:TR?= MVHTRW5ITVJ?
SW1116 M17VNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\Dd|hMUUN3ME2yNFcvODd5IN88US=> NH3ZVZJUSU6JRWK=
DBTRG-05MG NGrFd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHJR3A2UUN3ME2yNFcvQTB7IN88US=> NF\BdY9USU6JRWK=
SW982 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[wVm5KSzVyPUKwO{46PDhizszN Ml7kV2FPT0WU
RCM-1 NVu4T2dXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULqWpBXUUN3ME2yNVQvPzZ{IN88US=> NF33NFdUSU6JRWK=
COLO-320-HSR M4fEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJzNj6xNlUh|ryP NEjTPYhUSU6JRWK=
KNS-42 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr0OpZqUUN3ME2yNVYvPTd2IN88US=> MnrpV2FPT0WU
C2BBe1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXUXGZKSzVyPUKzNU46ODVizszN NWPOeFluW0GQR1XS
CCRF-CEM NFryb|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLZTWM2OD1{NEOuO|k2KM7:TR?= Mn30V2FPT0WU
SH-4 MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLzdHhKSzVyPUK0Ok4xQSEQvF2= M4jI[nNCVkeHUh?=
LS-1034 M1z6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTHeXBKSzVyPUK0Ok4zPjZizszN NUfCVphwW0GQR1XS
NCI-H2347 NILQ[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonMTWM2OD1{NEeuO|E{KM7:TR?= Mme4V2FPT0WU
RPMI-8866 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrzZ4pKSzVyPUK0PU4zPyEQvF2= M{jwVXNCVkeHUh?=
GAK NIL5bWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nr[mlEPTB;MkWzMlAxOiEQvF2= MoHoV2FPT0WU
NB6 MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[0TWM2OD1{N{CuNUDPxE1? NU\0NHA3W0GQR1XS
COLO-680N MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Xw[WlEPTB;MkeyMlUzPyEQvF2= MYnTRW5ITVJ?
RERF-LC-MS MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLQXIlKSzVyPUK3Ok4xODdizszN NYe5SW5iW0GQR1XS
TGBC11TKB NH3TU2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfFTWM2OD1{N{iuNVc5KM7:TR?= M4TIVHNCVkeHUh?=
C8166 M3\YVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTTTWM2OD1{N{iuOVA3KM7:TR?= M2LUTHNCVkeHUh?=
HDLM-2 NGTJcWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v5RmlEPTB;Mkm0MlQxQSEQvF2= M33ubnNCVkeHUh?=
IGR-1 NGrMZWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGT6N4tKSzVyPUK5OU43PTlizszN NEXHWIxUSU6JRWK=
FADU NH:0NVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJ7Nz61NUDPxE1? MlLDV2FPT0WU
L-428 M1\oXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzpR292UUN3ME2yPVcvPjF4IN88US=> M3XWPXNCVkeHUh?=
LU-65 M1LFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvGTWM2OD1|MESuN|Ih|ryP NHv3OJpUSU6JRWK=
HEL M1;teWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTNyOT65PFMh|ryP NHjwVoVUSU6JRWK=
NCI-H810 MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HNZ2lEPTB;M{GwMlU4KM7:TR?= MWfTRW5ITVJ?
C3A NWjMVIRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\RWmlEPTB;M{GxMlgxOiEQvF2= NYO3WG9CW0GQR1XS
NCI-H630 NYr3WVhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTN|Mj6yPVQh|ryP M2n0SHNCVkeHUh?=
KP-N-YN NYGzWG9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnWzTWM2OD1|NEGuNVI{KM7:TR?= M4HGcHNCVkeHUh?=
MOLT-13 M4LCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf5c4JKSzVyPUO0Nk4{OjZizszN NWPnNJlZW0GQR1XS
NCI-H1993 NHjGdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fRXGlEPTB;M{SyMlM3PSEQvF2= NVjMN405W0GQR1XS
BE-13 NFewemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fPbWlEPTB;M{S0MlE3PyEQvF2= NI\WNZZUSU6JRWK=
IST-SL1 M2Xu[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTN2Nz60NFEh|ryP NXH0V4szW0GQR1XS
TE-9 NXHjdpZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTN4Mz61PFkh|ryP NF;3TFVUSU6JRWK=
LU-135 M1HJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PmT2lEPTB;M{[3MlA{PSEQvF2= MoD1V2FPT0WU
T84 Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD5XIRKSzVyPUO3OE44OTJizszN NVHKWVROW0GQR1XS
K-562 M3PFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi4UmNNUUN3ME2zPFMvOzZizszN M{nMOnNCVkeHUh?=
SBC-5 MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTN6Nj65PFUh|ryP MUjTRW5ITVJ?
NB17 NFzOTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITvZoJKSzVyPUO5Nk42QTZizszN NEXn[o1USU6JRWK=
NCI-H2052 NIPjVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPJTWM2OD1|OUiuOFczKM7:TR?= NXHafHQ{W0GQR1XS
HCC38 M4H3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\pTWM2OD12MEGuOVk{KM7:TR?= MlnYV2FPT0WU
NCI-H69 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XlPWlEPTB;NESxMlA5OyEQvF2= MoDrV2FPT0WU

... Click to View More Cell Line Experimental Data
In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

Protocol

Kinase Assay:[4]
+ Expand

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
Cell Research:[2]
+ Expand
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • Concentrations: 0, 0.3, 1 and 3 μM
  • Incubation Time: 72 or 96 hours
  • Method: MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • Formulation: Formulated in 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
15% Captisol		 17 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.39
Formula

C25H21N5O.2HCl
CAS No. 1032350-13-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01306045 Recruiting Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 21, 2011 Phase 2
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Active, not recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

  • Selective Akt Inhibitor

    CCT128930 AKT2-selective, IC50=6 nM.

  • Most Potent Akt Inhibitor

    AZD5363 Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.

  • Akt Inhibitor in Clinical Trial

    Perifosine (KRX-0401) Phase III fro relapsed and refractory multiple myeloma.

  • Newest Akt Inhibitor

    AZD5363 Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Related Akt Products

  • Afuresertib (GSK2110183) New

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • AT13148 New

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • SC79 New

    SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

  • AZD5363

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • Triciribine

    Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

  • Honokiol

    Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID